Cancer Therapeutics in Drosophila melanogaster: A Closer Look at the ErbB Family of Receptor Tyrosine KinasesPublic
Downloadable Contentopen in viewer
The Epidermal Growth Factor Receptor (EGFR/ErbB) receptor tyrosine kinase (RTK) family has been implicated in numerous cancer types (e.g. lung, breast and brain) and this signaling network is conserved from Drosophila to humans. For this reason, Drosophila may provide an ideal in vivo system for experimental analyses of this pathway and a chemical genetics approach to the identification of therapeutics against it. Towards this goal, an assay utilizing Drosophila transgenic for members of the human ErbB family was developed for screening putative inhibitory compounds. Preliminary phenotypic data with known EGFR inhibitors yielded promising results.
- This report represents the work of one or more WPI undergraduate students submitted to the faculty as evidence of completion of a degree requirement. WPI routinely publishes these reports on its website without editorial or peer review.
- Date created
- Resource type
- Rights statement
- Last modified
- In Collection:
Permanent link to this page: https://digital.wpi.edu/show/wd375z00n